TY - JOUR
T1 - Maintenance therapy for CTCL
T2 - importance for prevention of disease progression
AU - Gordon, Emily R
AU - Trager, Megan H
AU - Kwinta, Bradley D
AU - Stonesifer, Connor J
AU - Lee, Kaitlyn J
AU - Adeuyan, Oluwaseyi
AU - Lapolla, Brigit A
AU - Akilov, Oleg E
AU - Enz, Paula A
AU - Guenova, Emmanuella
AU - Ortiz-Romero, Pablo L
AU - Papadavid, Evangelia
AU - Quaglino, Pietro
AU - Rozati, Sima
AU - Scarisbrick, Julia J
AU - Litman, Thomas
AU - Geskin, Larisa J
PY - 2024/12
Y1 - 2024/12
N2 - There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.
AB - There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Communicable Disease Control
KW - COVID-19/prevention & control
KW - Disease Progression
KW - Lymphoma, T-Cell, Cutaneous/therapy
KW - Maintenance Chemotherapy/methods
KW - Mechlorethamine/administration & dosage
KW - Neoplasm Staging
KW - Phototherapy/methods
KW - Retrospective Studies
KW - SARS-CoV-2
KW - Skin Neoplasms/therapy
KW - Treatment Outcome
UR - https://www.scopus.com/pages/publications/85197717512
U2 - 10.1080/10428194.2024.2376164
DO - 10.1080/10428194.2024.2376164
M3 - Article
C2 - 38975910
SN - 1029-2403
VL - 65
SP - 1883
EP - 1890
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -
